31 results about "Model protein" patented technology

A computerized method of computing the Voronoi diagram has applications including communications networks, robotics, three-dimensional networks, materials science, searching image processing, data clustering, data compression, control of a groups of methods for image processing and the like, design of electronic circuits, geographic information systems, solutions of the efficient location problem, face recognition, mesh generation and re-meshing, curve and surface generation/reconstruction, solid modeling, collision detection, controlling motion of vehicles, navigation, accident prevention, data clustering and data processing, proximity operations, nearest neighbor search, numerical simulations, weather prediction, analyzing and modeling proteins and other biological structures, designing drugs, finding shortest paths, pattern recognition and as an artistic tool. The Voronoi diagram is a decomposed region X made into cells, the decomposition being induced by a set of generators (P_k)_k-K, and a distance function, and involves finding for each generator P_k a cell, which is a set of all the points in X satisfying the condition that the distance to the current generator P=P_k is not greater than the distance thereof to the union A of the other generators, The method comprising: for each generator, and for each point p in this generator, selecting a set of directions, then for each direction recursively testing a ray in that direction, until a certain interval on the ray is of length less than or equal to a given error parameter. A point corresponding to the interval on the ray is then selected as an end point, the cells are defined from the end points, thus forming the Voronoi diagram.

The gene clone and expression of Japonese lampreyí»s oral gland model proteins RGD with antineoplastic action are disclosed. Three cDNA sequences with said model proteins RGD and their clones, the protein sequence and its expression in engineered bacteria, and the action of proteins RGD in closing the signal transfer channel to suppress the vascular neogenesis and tumor cell reproduction for antineoplastic purpose are also disclosed.

The invention belongs to the field of biotechnologies, and relates to a method for applying recombinant expression separated and purified human-derived protein Fn3 (fibronectin type III domain) mutants as N-glycosylation efficiency detection model proteins. The method includes steps of constructing Fn3-Gly-loop recombinant protein gene expression vectors of the Fn3 mutants; jointly transforming the constructed expression vectors into Escherichia coli engineering strains CLM37 by means of electric shock processes; screening the expression vectors by the aid of antibiotics to obtain positive clones. Recombinant proteins contain Fn3-Gly-loop proteins which are about to be modified by recombinant glycosyl, and the Fn3-Gly-loop fusion protein glycosylation efficiency can be detected by the aid of Western Blot processes. The method has the advantages that the skeleton proteins Fn3 in Escherichia coli are used as receptor proteins, accordingly, the model receptor proteins suitable for N-glycosylation modification efficiency research can be constructed, and the recombinant protein glycosylation efficiency can be easily, quickly and efficiently detected in the Escherichia coli.

The invention relates to a method for preparing a protein molecular engram block polymer. Functional monomers, crosslinking agents and model protein molecules in proper proportions stand for 2 to 5 minutes at the temperature ranging from 0 to 4 DEG C, and a certain amount of evocating agents and rate accelerating materials are orderly added later. The mixture is put under the environment whose temperature ranges from minus 5 DEG C to minus 20 DEG C after being rapidly injected into a liquid chromatogram column jacket and polyreaction is completed within 1 to 12 hours. The model protein molecules are eluted by dodecyl sodium sulfate whose weight concentration is 10 percent and acetic acid solution whose volume concentration is 10 percent, namely, a macroporous protein molecular engram monolithic column can be prepared. The invention has the advantages as follows: the preparation method is simple and reliable, and the obtained protein molecular engram monolithic column has stronger template molecule recognition property. The technique provides a novel preparation method for developing protein molecular engram monolithic column.

The invention discloses a method for preparing colon-targeted microcapsules by using a microfluid technology. The method comprises the following steps of S1, dissolving modified chitosan in an acetic acid aqueous solution, regulating the pH value to 7.0, and dissolving a photoinitiator and model protein in the acetic acid aqueous solution to obtain an internal phase solution; S2, dissolving ethyl cellulose in dichloromethane to prepare an intermediate phase solution; S3, dissolving polyvinyl alcohol in pure water to prepare a continuous phase solution; S4, wrapping the internal phase solution obtained in the step S1 in droplets of the intermediate phase solution obtained in the step S2, dispersing the droplets in the continuous phase solution obtained in the step S3, and preparing a W/O/W emulsion in one step; S5, irradiating the emulsion obtained in the step S4 with ultraviolet light to solidify the inner phase into a spherical core, and heating to volatilize the organic solvent completely to solidify the intermediate phase into a capsule shell; and S6, washing the microcapsules cured in the step S5 with pure water for multiple times, and performing freeze drying. The microcapsules prepared by the method has a colon-specific release effect and is used for protein embedding and oral delivery.

A gene clone and expression of the oral gland KGD pattern protein of Japanese lamprey with anti-thrombosis is disclosed. Its cDNA sequence and clone, its relative protein sequence, its expression in colibacillus and Piohia yeast, its combination with the glucoprotein gpó�b/IIIa on cell membrane of platelet to suppress the platelet coagulation, and its application in developing the anti-thrombosis medicines are disclosed.

The invention belongs to the technical field of magnetic relaxation switch detection, in particular to a magnetic relaxation switch based on Fe3O4 at Au and a preparation method thereof. Probes adopted by the magnetic relaxation switch of the invention are flower-shaped magnetic nanometer particles with identification marks decorated on the surfaces, and the flower-shaped magnetic nanometer particles are in Fe3O4 at Au nuclear shell structures, the particle diameter of the probes is ranged from 50 to 70nm, and the relaxation degree R2 of the probes is 9.35 mM<-1>.s<-1>. Through decorating identification molecular biotin on gold layers of the nanometer particle surfaces, the invention realizes the fast, simple and convenient detection of the model protein Avidin, and the detection limit is as low as the level of 10 nM. The invention solves the problems of inconvenient implementation and unstable detection results of the existing magnetic relaxation switch technology.

The invention relates to a glucosan-based cryogel microsphere separating medium with superlarge pores for biological separation and a preparation method of the glucosan-based cryogel microsphere separating medium. The glucosan-based cryogel microsphere separating medium is characterized in that supermacroporous glucosan-based cryogel microspheres are porous particles; particles sizes of the supermacroporous glucosan-based cryogel microspheres are 490 to 2000(mu)m, the aperture is 1 to 30(mu)m, and the porosity is 78 to 96 percent; the adsorption capacity to lysoenzyme model protein reaches 5.2 to 10mg/mL cryogel. The invention also provides a method for preparing the cryogel microspheres by using micro-fluidic forming, phase transformation crystallization hole forming and cross linking. The cryogel microsphere separating medium provided by the invention has the advantages of the superlarge pores, good biocompatibility, excellent permeability, high porosity, greater adsorption capacity to protein, good biological safety and the like. The preparation method provided by the invention is simple, and has a broad application prospect in the field of biological separation; particle sizes of the particles are uniform.

The invention provides a polylactic acid-cladded protein peptide vaccine, a protein peptide vaccine carrying system for a protamine-cladded polylactic acid nanocapsule and a preparing method of the carrying system. Ovalbumin (OVA) is used as a model protein peptide vaccine, and an OVA solution is dispersed in a PLA-containing methylene dichloride organic phase by a probe ultrasonography method to form a primary emulsion. The primary emulsion is added into a polyvinyl alcohol containing external aqueous phase and treated by probe ultrasonography to form a multiple emulsion. A cured OVA/PLA microcapsule is obtained after the methylene dichloride organic phase is fully volatilized through agitating. Protamine (PS) is added into an OVA/PLA microcapsule suspension and agitated to obtain an OVA/PLA/PS microcapsule. The OVA/PLA/PS microcapsule has stable nanometer grain size, stable dispersing coefficient and surface potential suitable for transfect cells. The extracting capability of bone marrow derived dendritic cells (BMDC) for the OVA/PLA/PS microcapsule can be effectively improved. The expression of BMDC surface molecules MHCI, MHCII, CD83 and CD86 is obviously improved, and the secretion of a BMDC polarizing factor IL-12p70 is increased.

The invention relates to a method for producing turbot immunoglobulin, which is characterized in that the turbot is immunized by using bovine serum albumin BSA as an antigen; specifically, after three immunization operations, after the first immunization The anti-BSA immunoglobulin of turbot was obtained by affinity chromatography within 8 to 10 weeks. The invention overcomes the conventional usage of BSA in the field of biochemistry, and uses it as an antigen to immunize turbot through a specific immunization procedure, so as to obtain high titer anti-BSA specific antibody. The method of the invention solves the long-standing problem of lack of sufficient specific immunoglobulin in turbot immunization research. The BSA used at the same time has the advantages of simple structure, single component, not easy to interfere with immune results, and easy to obtain. BSA can be established as a model protein in aquatic animals, and a research model based on BSA can be formed.

The invention discloses application of gold a nano-cluster in detection of protein amyloid fibrosis in a biological sample and screening of inhibitors. According to the invention, lysozyme is used asa model protein, research finds that the fluorescence intensity of a gold nano-cluster is enhanced along with the increase of the lysozyme fiber concentration, and the lysozyme fiber concentration andthe fluorescence intensity are in a linear relationship within a certain concentration range, so that the gold nano-cluster can be applied to the detection of a protein amyloid fibrosis process in abiological sample. Compared with a fluorescence method using traditional organic dye thionein T (ThT), the method has the advantages that the sensitivity is high, the gold nano-cluster has the advantages of low toxicity and large Stocks displacement, and the fluorescence signal of the gold nano-cluster is sensitive to change along with the degree of protein fibrosis, so that the change of the protein from the initial stage of fibrosis to the logarithmic phase can be detected more sensitively, the process and mechanism of protein amyloid fibrosis can be studied more effectively, and the gold nano-cluster can be used for screening inhibitors of protein amyloid fibrosis.

Electrochemical microscopes gradually develop in decades in the past and are used for imaging single-cell biomolecules; however, it is difficult to achieve electrochemical visualization of intracellular proteins in a single cell. According to the application, a model protein (KDM1/LSD1 antigen) in a cell nucleus of an MCF 7 cell is observed by using a wireless bipolar electrochemiluminescence technology (BPE-ECL) for the first time. The submicron-sized single-walled carbon nanotube is connected with the antibody and is used for identifying the corresponding KDM1/LSD1 antigen. Under a low electric field of 1000V/cm, L012 (luminol analogue) is subjected to electrochemical oxidation at the anode end of the nanotube, and an ECL signal is emitted, so that wireless visualization of the position of the nanotube is realized. Under the condition that an externally applied voltage which is low enough is used, bipolar ECL emission on a cell nucleus in a single cell can be observed, and electrochemical imaging of a KDM1/LSD1 antigen in the single cell is supported.

Chemical conjugation is commonly used to enhance the pharmacokinetics, biodistribution, and potency of protein therapeutics, but often leads to non-specific modification or loss of bioactivity. Here, we present a simple, versatile and widely applicable method that allows exquisite N-terminal specific modification of proteins. Combining reversible side-chain blocking and protease mediated cleavage of a commonly used HIS tag appended to a protein, we generate with high yield and purity exquisitely site specific and selective bio-conjugates of TNF-α by using amine reactive NHS ester chemistry. We confirm the N terminal selectivity and specificity using mass spectral analyses and show near complete retention of the biological activity of our model protein both in vitro and in vivo murine models. This methodology is applicable to a variety of potentially therapeutic proteins and the specificity afforded by this technique allows for rapid generation of novel biologics.

The present invention relates to a method for determining the highest temperature that is suitable for performing accelerated protein stability studies, as well as to a method for modeling real-time protein stability from accelerated stability data generated at said temperature.

The invention relates to a method for preparing a stable zymoprotein ring through a precise regulation and control assembly. The method comprises the following steps that by taking aldo-keto reductase as model protein, 4-azido-L-phenylalanine is inserted at a fixed point to obtain two mutants of the aldo-keto reductase; then, under the action of microwaves, a diacetylene crossing agent induces covalent assembly of the target enzyme protein of a cell lysis solution; and the morphology of the zymoprotein assembly is regulated and controlled by controlling the protein concentration, the mutation site and the dosage of the cross-linking agent in the cell lysis supernatant, and the cyclic cross-linked zymoprotein is obtained. According to the method disclosed by the invention, the cyclic assembly of zymoprotein is formed only by using the cell lysis solution by utilizing the biological orthogonal chemical specific connection between non-natural amino acid molecules in the protein and cyclooctyl diacetylene. the zymoprotein ring obtained by the invention shows strong catalytic activity, thermal stability and digestion stability in simulated gastric juice and intestinal juice, so that the application of the zymoprotein ring in catalysis and drug delivery materials becomes possible.